Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 200.77 M | 135.24 M | 399.78 M | 1.32 B | 656.24 M |
2022 | 118.02 M | 26.47 M | 321.21 M | 1.02 B | 614.81 M |
2021 | 108.76 M | 63.03 M | 245.26 M | 905.03 M | 528.08 M |
2020 | 96.64 M | 11.78 M | 160.2 M | 718.97 M | 407.2 M |
2019 | 106.55 M | 52.4 M | 191.78 M | 623.17 M | 338.34 M |